The search for better sleep solutions for children may be one step closer, as Idorsia Pharmaceuticals announced promising results from a Phase 2 clinical trial of Quviviq (daridorexant) in pediatric patients struggling with insomnia. The trial, focused on children and adolescents with neurodevelopmental disorders—specifically autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD)—showed significant improvements in sleep onset and maintenance. This represents a potential breakthrough, as treatment options for insomnia in this population are currently limited and often involve off-label use of medications originally intended for adults.
Quviviq, already approved by the Food and Drug Administration (FDA) for adults with insomnia, works by blocking orexin, a neurotransmitter that promotes wakefulness. The Phase 2 trial, detailed in a company press release on November 28, 2023, involved 62 participants aged 6 to 17. Researchers measured sleep using polysomnography – a comprehensive sleep study – over a two-week period. The data indicated that Quviviq led to statistically significant improvements in both subjective and objective measures of sleep, without revealing any new safety concerns.
The challenges of pediatric insomnia are often intertwined with underlying neurodevelopmental conditions. Children with autism or ADHD frequently experience difficulties falling asleep, staying asleep, or both. These sleep disturbances can exacerbate behavioral issues, impair cognitive function, and negatively impact overall quality of life for both the child and their family. “Sleep problems are incredibly common in children with neurodevelopmental disorders, and they can have a cascading effect on daytime functioning,” explains Dr. Anne Marie Morse, a pediatric sleep specialist at Boston Children’s Hospital, in a separate interview with time.news. “Finding safe and effective treatments is a critical need.”
Trial Details and Key Findings
The Phase 2 trial was a randomized, double-blind, placebo-controlled study. Participants were randomly assigned to receive either Quviviq or a placebo for two weeks. The primary endpoint of the study was the change from baseline in sleep onset latency – the time it takes to fall asleep – as measured by both patient diaries and polysomnography. Secondary endpoints included measures of sleep maintenance, wake after sleep onset, and overall sleep efficiency.
According to Idorsia, Quviviq demonstrated a statistically significant reduction in sleep onset latency compared to placebo, as measured by polysomnography. Improvements were similarly observed in other sleep parameters, suggesting that the medication may help children not only fall asleep faster but also stay asleep longer. The company reported that the treatment was generally well-tolerated, with no unexpected adverse events. However, it’s important to note that Phase 2 trials are designed primarily to assess safety and preliminary efficacy; larger, Phase 3 trials are needed to confirm these findings.
What Makes Pediatric Insomnia Different?
Treating insomnia in children isn’t simply a matter of adapting adult dosages. Several factors distinguish pediatric insomnia from its adult counterpart. Developmental stages, co-existing medical conditions, and behavioral patterns all play a role. “Children’s brains and bodies are still developing, so they may respond differently to medications than adults,” Dr. Morse notes. “It’s also crucial to address any underlying behavioral issues that may be contributing to the sleep problems.”
the causes of insomnia in children with neurodevelopmental disorders are often complex. Sensory sensitivities, anxiety, and difficulty regulating emotions can all interfere with sleep. A comprehensive approach to treatment typically involves a combination of behavioral therapies, such as establishing a consistent bedtime routine and creating a relaxing sleep environment, and, in some cases, medication.
The Role of Orexin and Quviviq’s Mechanism
Orexin, also known as hypocretin, is a neuropeptide that plays a key role in regulating wakefulness, arousal, and appetite. It’s produced by a slight group of neurons in the hypothalamus. Quviviq selectively blocks orexin receptors, effectively reducing the drive to stay awake. This mechanism differs from some older sleep medications, such as benzodiazepines, which have a more generalized effect on the central nervous system and carry a higher risk of side effects.
The selectivity of Quviviq is one reason why it has garnered attention as a potential treatment for insomnia. However, even with a targeted mechanism, careful monitoring for side effects is essential, particularly in vulnerable populations like children. Common side effects observed in adult trials of Quviviq include daytime sleepiness and dizziness. The Phase 2 pediatric trial did not reveal any new safety signals, but further investigation is warranted.
Next Steps: Phase 3 Trials and Potential Approval
Idorsia is now planning to initiate Phase 3 clinical trials of Quviviq in pediatric patients with insomnia. These larger, more rigorous trials will be crucial for confirming the efficacy and safety of the medication and for providing the data needed to support a potential FDA approval for this indication. The company anticipates beginning these trials in the first half of 2024.
If the Phase 3 trials are successful, Quviviq could become the first medication specifically approved for the treatment of insomnia in children with neurodevelopmental disorders. This would represent a significant advance in the field of pediatric sleep medicine and offer hope to families struggling with the challenges of childhood insomnia. The potential impact extends beyond improved sleep; better sleep can lead to improvements in behavior, learning, and overall well-being.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
Have you or a loved one struggled with pediatric insomnia? Share your experiences and thoughts in the comments below. Please also share this article with anyone who might find it helpful.
